ClinicalTrials.Veeva

Menu

Antibiotic Therapy After Incision and Drainage for Abscess

Wake Forest University (WFU) logo

Wake Forest University (WFU)

Status

Withdrawn

Conditions

Abscess

Treatments

Drug: Placebo
Drug: Trimethoprim/Sulfamethoxazole (Bactrim)
Procedure: Incision and drainage

Study type

Interventional

Funder types

Other

Identifiers

NCT00900510
IRB00008450

Details and patient eligibility

About

Background: Skin abscesses are a growing problem in the general pediatric population around the world. While the standard treatment for an abscess/boil is incision and drainage, many physicians also prescribe antibiotics, despite the lack of evidence that antibiotics are necessary to help the wound heal. The purpose of this research study is to determine whether antibiotics are necessary after incision and drainage of a skin abscess in children. This is an important question because medical evidence has shown that using antibiotics when they are not needed has contributed to the increase of bacterial antibiotic resistance. In fact, several of the antibiotics that successfully killed Staph bacteria several years ago are now no longer effective because of antibiotic resistance. Now resistant forms of Staph bacteria, called "Community-Acquired Methicillin-Resistant Staph Aureus" (CA-MRSA), account for 50-85% of all pediatric skin abscesses. If antibiotics are not necessary then withholding them when appropriate may help slow the progression of antibiotic-resistant Staph infections.

Objective(s) and Hypothesis(es): The investigators believe that antibiotics are no better than placebo at achieving a cure after drainage of an abscess in a child. The objective of this study is to answer the question: Do antibiotics after abscess drainage result in a better chance of cure than placebo?

Potential Impact: If abscess drainage alone is shown to be as effective as drainage followed by antibiotics, then the routine use of antibiotics for this problem could be avoided. This would help limit the increasing antibiotic resistance of bacteria (especially CA-MRSA) in communities around the world. A well-designed study may provide the evidence to change the way children are treated for abscesses in a future where antibiotic resistant bacteria will be even more of a public health challenge.

Sex

All

Ages

6 months to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Any child (age 6 months-18 years old) that:

    • does not meet criteria for hospitalization and
    • has only one localized abscess (>/= 2 cm of erythema and induration), which is clinically judged to be amenable to incision and drainage. (i.e., on clinical exam their is fluctuance, erythema, induration, and/or purulent drainage)
    • has an abscess that is ± 7 days from onset, who requires surgical incision and drainage for a skin and soft-tissue abscess

Exclusion criteria

  • children < 6 months of age
  • children who require inpatient hospitalization - children with a medical condition in which adjuvant antibiotic therapy would be accepted standard of practice (i.e., history of neutropenia, cardiac surgery, indwelling prosthesis)
  • children with a previously diagnosed immunodeficiency (HIV, Chronic Granulomatous Disease, Job's syndrome, chronic steroid use)
  • children hospitalized within 2 months of presentation (due to higher rate of nosocomial MRSA colonization)
  • abcesses located on the head or neck
  • children with history of a sulfa allergy
  • abscesses caused by animal bite wounds
  • children with Diabetes Mellitus
  • abscesses arising from tattooing
  • abscesses arising from vaccination sites
  • pregnant females

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

0 participants in 2 patient groups

Drainage and placebo
Experimental group
Description:
Incision and drainage with placebo.
Treatment:
Drug: Placebo
Procedure: Incision and drainage
Drainage with TMP/SX
Active Comparator group
Description:
Drainage with Bactrim
Treatment:
Drug: Trimethoprim/Sulfamethoxazole (Bactrim)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems